LeePH, StocktonMD, FranksAS. Acute pancreatitis associated with liraglutide. Ann Pharmacother, 2011; 45:e22.
5.
ElashoffM, MatveyenkoAV, GierB, ElashoffR, ButlerPC. Pancreatitis, pancreatic and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology, 2011; 141:150–156.
6.
IyerSN, DrakeAJ, WestRI, MendezCE, TanenbergRJ. Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide. Endocr Pract, 2012; 18:10–13.
7.
FranksAS, LeePH, GeorgeCM. Pancreatitis: a potential complication of liraglutide?Ann Pharmacother, 2012; 46:1547–1553.
8.
FamularoG, GasbarroneL, MinisolaG. Pancreatitis during treatment with liraglutide. JOP, 2012; 13:540–541.
9.
SueM, YoshiharaA, KubokiK, HiroiN, YoshinoG. A case of severe acute necrotizing pancreatitis after administration of sitagliptin. Clin Med Insights Case Rep, 2013; 6:23.
10.
KoehlerJA, BaggioLL, LamontBJ, AliSD, DruckerDJ. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes, 2009; 58:2148–2161.
11.
NachnaniJS, BulchandaniDG, NookalaA, HerndonB, MolteniA, PandyaP, TaylorR, QuinnT, WeideL, AlbaLM. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia, 2010; 53:153–159.
12.
TatarkiewiczK, SmithPA, SablanEJ, PolizziCJ, AumannDE, VillescazC, HargroveDM, GedulinBR, LuMGW, AdamsL, WhisenantT, RoyD, ParkesDG. Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodentsd. Am J Physiol Endocrinol Metab, 2010; 299:E1076–E1086.
13.
NyborgNC, MoickAM, MadsenLW, KnudsenLB. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes, 2012; 61:1243–1249.
14.
ButlerAE, Campbell-ThompsonM, GurloT, DawsonDW, AtkinsonM, ButlerPC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes, 2013; 62:2595–2604.
15.
KahnSE. Incretin therapy and islet pathology—a time for caution. Diabetes, 2013; 62:2178–2180.
16.
CohenD. Has pancreatic damage from glucagon suppressing drugs been underplayed?BMJ, 2013; 346:f3680.
17.
LopesRD, DickersonS, HafleyG, BurnsS, Tourt-UhligS, WhiteJ, NewbyLK, KomajdaM, McMurrayJ, BigelowR, HomePD, MahaffeyKW. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. Am Heart J, 2013; 166:208–216.
18.
MahaffeyKW, HafleyG, DickersonS, BurnsS, Tourt-UhligS, WhiteJ, NewbyLK, KomajdaM, McMurrayJ, BigelowR, HomePD, LopesRD. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J, 2013; 166:240–249.
19.
BachRG, BrooksMM, LombarderoM, GenuthS, DonnerTW, GarberA, KennedyL, MoradS, Pop-BusuiR, KelseySF, FryeRL. Rosiglitazone and outcomes for patients with diabetes and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 diabetes trial. Circulation, 2013; 128:785–794.
20.
LabuzekK, KozlowskiM, SzkudlapskiD, SikorskaP, KozlowskaM, OkopienB. Incretin-based therapies in the treatment of type 2 diabetes—more than meets the eye. Eur J Intern Med, 2013; 24:207–212.
21.
ScheenA. Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis. Expert Opin Drug Saf, 2013; 12:545–557.
22.
DoreDD, SeegerJD, ChanKA. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Res Med Opin, 2009; 25:1019–1027.
23.
NoelRA, BraunDK, PattersonRE, BloomgrenGI. Increased risk of acute pancreatitis, biliary disease observed in patients with type 2 diabetes. A retrospective cohort study. Diabetes Care, 32:834–838.
24.
GargR, ChenW, PendergrassM. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin. A retrospective observational pharmacy claims analysis. Diabetes Care, 2010; 33:2349–2354.
25.
DoreDD, BloomgrenGL, WentenM, HoffmanC, CliffordCR, QuinnSG, BraunDK, NoelRA, SeegerJD. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab, 2011; 13:559–566.
26.
WentenM, GaeblerJA, HusseinM, PelletierEM, SmithDB, GiraseP, NoelRA, BraunDK, BloomgrenGL. Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study. Diabet Med, 2012; 29:1412–1418.
27.
RomleyJA, GoldmanDP, SolomonM, McFaddenD, PetersAL. Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population. Diabetes Technol Ther, 2012; 14:904–911.
28.
SinghSS, ChangH-Y, RichardsTM, WeinerJP, ClarkJM, SegalJB. Glucagonlike peptide-1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus. JAMA Intern Med, 2013; 173:534–539.
29.
EngelSS, Williams-HermanDE, GolmGT, ClayRJ, MachotkaSV, KaufmanKD, GoldsteinBJ. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract, 2010; 64:984–990.
30.
MacConellL, BrownC, GurneyK, HanJ. Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials. Diabetes Metab Syndr Obes, 2012; 5:29–41.
31.
EngelSS. Incidence of pancreatitis, PDCA in clinical studies of sitagliptin. Presented at the NIDDK Pancreatitis–Diabetes–Pancreatic Cancer Workshop, June 12–13, 2013, NIH Campus, Bethesda, MD, 84.
32.
MosesAC, RasmussenM, KnudsenLB. No evidence of a risk of pancreatitis or PDAC with liraglutide therapy. Presented at the NIDDK Pancreatitis–Diabetes–Pancreatic Cancer Workshop, June 12–13, 2013, NIH Campus, Bethesda, MD, 83.
33.
SciricaBM, BhattDL, BraunwaldE, StegPG, DavidsonJ, HirshbergB, OhmanP, FrederichR, WiviottSD, HoffmanEB, CavenderMA, UdellJA, DesaiNR, MozensonO, McGuireDK, RayKK, LeiterLA, RazI. the SAVOR-TIMI 53 Steering Committee and Investigators: Saxagliptin, cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med, 2013Sep2[Epub ahead of print].10.1056/NEJMoa1307684.
34.
WhiteWB, CannonCP, HellerSR, NissenSE, BergenstalRM, BakrisGL, PerezAT, FleckPR, MehtaCR, KupferS, WilsonC, CushmanWC, ZannadF. the EXAMINE Investigators: Alogliptin after acute coronary syndrome in patients with type 2 diabetes mellitus. N Engl J Med, 2013Sep2[Epub ahead of print].10.1056/NEJMoa1305889.
35.
SprangerJ, Gundert-RemyU, StammschulteT. GLP-1 based therapies: the dilemma of uncertainty. Gastroenterology, 2011; 141:150–156.
36.
IyasuS. FDA's approach to addressing a pancreatic safety signal with incretin mimetics: pharmacovigilance, pharmacoepidemiology. Presented at the NIDDK Pancreatitis–Diabetes–Pancreatic Cancer Workshop, June 12–13, 2013, NIH Campus, Bethesda, MD, 90–91.
37.
HarjaE, LordJ, SkylerJS. An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology. Diabetes Technol Ther, 2013; 15:609–618.
38.
GierB, ButlerPC. Glucagonlike peptide-1 based drugs, pancreatitis. Clarity at last, but what about pancreatic cancer. JAMA Intern Med, 2013; 173:539–541.
39.
CohenD. Two drugs for type 2 diabetes seem to raise risk of acute pancreatitis, study shows. BMJ, 2013; 346:f1304.
40.
GaleEAM. GLP-1 based agents, acute pancreatitis. Drug safety falls victim to the three monkey paradigm. BMJ, 2013; 346:f1263.
41.
ButlerPC, ElashoffM, ElashoffR, GaleEA. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe?Diabetes Care, 2013; 36:2118–2125.
42.
WooJS, KimW, HaSJ, KimJB, KimSJ, KimWS, SeonHJ, KimKS. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary pericutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscler Thromb Vasc Biol, 2013; 33:2252–2260.
43.
NauckM. A critical analysis of the clinical use of incretin-based therapies. The benefits far outweigh the potential risks. Diabetes Care, 2013; 36:2126–2132.
